November 1989, Volume 39, Issue 11

Case Reports

HAIRY CELL LEUKAEMIA

M. Tariq  ( Department of Medicine, Ayub Medical College, Abbottabad. )
M.A. Khaliq  ( Department of Pathology, Ayub Medical College, Abbottabad. )
A. Karim Saeed  ( Department of Medicine, Ayub Medical College, Abbottabad. )

INTRODUCTION

Hairy cell leukaemia is a rare form of lymphoproliferative disease that affects 2% of leukaemia patients and was first described in 1958 as leukaemic reticuloendotheliosis1. The typical presentation is pancytopenia, splenomegaly and abnormal lymphoid cells in blood with hairy cytoplasmic projections2,3. The pathological hairy cell resembles in many ways B-lymphocyte4 as in chronic lymphocytic leukaemia (CLL). The disease occurs predominantly in older males, median age 50 years, and male/female ratio is 4:1. It is important to differentiate it from CLL because of its different behaviour and manage­ment2,5.

CASE REPORT

Mr. S.Z., a 47 year old male presented in June 1985 with a history of mass in the left upper abdomen and general weakness. He had 8 cms palpable spleen, no hepatomegaly and minimal lymphadenopathy, all other systems were normal. Blood count showed a haemoglobin of 12.6 g/dl, platelets of 185000/cmm, total leucocyte count of 190,000/cmm with 3% neutrophils and 97% of lymphocytes which were mature cells of small and medium type. Bone marrow report showed “a diluted marrow with no marrow particles and marked infiltration by mature lymphocytes”. A diagnosis of chronic lymphocytic leukaemia (CLL) was made and the patient was started on chlorambucil 6 mg and deltacortril 20 mg orally daily. After one month of therapy the TLC was 136,000/cmm, chlorambucil was increased to 10 mg daily. On 16 July TLC was 128,000/cmm, his general weakness had increased and there was intermittent low grade fever. The patient was lost to follow up for 4 months. He came to the hospital on 11/11/85 with a haemoglobin of 13.2 Wdl and a TLC of 128,000/cmm. As he had discontinued our treatment, he was restarted on chlorambucil 6 mg and Prednisolone 20 mg daily. In view of poor response to therapy and patient’s increasing sple­the size and symptoms, his clinical findings and blood cytology were critically reviewed. It was noted that many of the larger lymphocytes had hairy cytoplasmic projections; diagnosis was, the­refore, revised to hairy cell leukaemia. Bone marrow cytochemistry showed these cells to be Sudan Black-Neg. PAS-Neg, a naphthal acetate­Neg, but Tartrate resistant Acid Phosphatase (TRAP), positive4. Chlorambucil and Predniso­lone were therefore continued in low doses but his drug compliance was unsatisfactory. By January 1986 his TLC count had come down to <45,000/cm, spleen had slightly regressed and his general condition had much improved. He was advised splenectomy to which he did not agree so he was managed on intermittent Chlorambucil and Pred­nisolone. His spleen, however, showed progres­sive enlargement and was about 12 cm, below the costal margin by November 1986 and his TLC was above 105/cmm. As 2 interferon was not available locally so the previous therapy was continued. The patient was lost to follow up from December 1986 until 29/4/87 when he was seen again had a high grade temperature, body pains, heaviness in the abdomen and his general condition was poor. His blood counts showed a haemoglobin of 12.8 gm/dl, platelets of 78,000/cmm and TLC of 386,000/cmm. Besides other supportive treatment he was started on CVP regimen of Cyclophosphamide 500mg i/v weekly x4, Vincristine 2mg i/v weekly x 4, and Prednisolone 60 mg orally daily for six weeks. During the next 6 weeks his condition improved and on 2.6.1987 his counts were haemoglobin of 10 g/dl, Platelets of 96,000/cmm, and TLC = 72,000/ cmm. From July 1987 to September, 1988 he has bad 4 courses of a2 interferon each of 4.5 million units subcutaneously on alternate days x 12 injec­tions. The deviation from the recommended treatment schedule of 3 million units daily was due to non-availability of the drug here and its very high cost. During each course the patient had severe “flu like” symptoms, high temperature, body aches and low performance index. His blood counts and subjective feeling of well being had been much better after each course compared to previous Chiorambudil and Prednisolone/CVP therapy. Due to non availability of interferon, the disease process in this patient could not be controlled effectively, although his response to this drug bad been quite from good. His last blood counts done in September, 1988 were haemo­globin of 6.8 g/dl, TLC of 380,000/ cmm and spleen was 24 cmm. We therefore, intend to combine leukapheresis with Chlorambucil/ Prednisolone therapy for future management of this case.

DISCUSSION

Lymphopro literative disorders are now ex­tensively classified on the basis of surface markers on the lymphoid cells. This has enabled better management of these disorders. Hairy cell leuka­emia is a slow progressive chronic disorder and is considered a variant of CLL which it closely resembles. In fact, this patient was initially diag­nosed as CLL, but due to his poor response to conventional therapy his diagnosis was re-eva­luated. He had all the features of hairy cell lcukaemia, i.e., hairy lymphoid cells in the blood, pancytopaenia, splenomegaly and marrow that was difficult to aspirate. These cases should be differentiated from CLL because they respond poorly to chemotherapeutic agents like Chioram­buci! besides which these drugs may further suppress the normal cells of the marrow. These patients used to be treated with splenec to my and intermittent Prednisolone but the over-all treat­ment has been unsatisfactory. Recently dramatic results have been repor­ted with a2 interferon. This newer compound is now freely available in a highly purified form, made possible by monoclonal recombinant DNA technique. In hairy cell leukaemia which had hitherto no satisfactory drug for treatment, interferon is the first agent to bring about significant control of disease process. There are multicentric reports of 90% complete/partial remissions in patients in­cluding those who did not do well on other chemotherapeuticagents and splenectomy. These patients suffer from low granulocyte values, in­creased infections, decreased platelets and hae­moglobin levels. Treatment with interferon has resulted in improvement of some or all the above haematological variables at sometime during the­rapy. In our patient the results of interferon treatment were encouraging but its irregular sup­ply and high cost precluded its continual use and potential benefits.

REFERENCES

1. Bouroncle, B.A., Wiseman, B.K. and Doan, C.A. Lcu­kaemic reticuloedotheliosis. Blood, 1958; 13:609.
2. Burke, J.S., Byhne, G.E. Jr. and Rappaport, H. (Leu­kaemic reticuloendotheliosis) Hairy Cell Leukaemia. A clinical pathologic study of 21 patients. Cancer, 1974;33:1399.
3. Catovsky, D., Pettit, J.E., Galton, D.A.G. and Harrison, C.V. Leukaemic reticuloendotheliosis (‘Haiiy Cell Lcu­kaemia); a distinct clinico-pathological entity. Br. J. Hae­matol., 1974; 26:9.
4. Rieber, E.P., Hadam, M.R., Linke, R.P., Saal, J.G., Riet­hmuller, G., Von Heyden, H.W. and Wailer, H.D. Hairy cell leukaemia; surface markers and functional capacities of leukaemic cells analysed in eight patients. Br. J. Hae­matol., 1979; 42:175.
5. Golomb, H.M. Hairy cell leukaemia; an unusual lym­phoproliferative disease. A study of 24 patients. Cancer, 1978; 42:946.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: